Risk Factors for Major Bleeding among Patients with Chronic Kidney Disease Treated with Acetylsalicylic Acid
Kidney and Blood Pressure Research · 2024
DOI: 10.1159/000542500 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney and Blood Pressure Research, 2024. Verfasst von Gil Schwartz Yoskovitz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Aspirin, Renal Insufficiency, Chronic, Hemorrhage, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Individuals with chronic kidney disease (CKD) are at increased risk of thrombotic events and bleeding. Acetylsalicylic acid (ASA), an effective antiplatelet agent, is one of the most frequently used medications for both primary and secondary prevention of cardiovascular disease (CVD). However, it can also contribute to bleeding events due to its inherent antiplatelet effect. The objective of this study was to determine the characteristics of CKD patients at increased risk of bleeding under ASA therapy.
Methods
This retrospective analysis included patients with non-dialysis-dependent CKD who were treated with ASA for primary prevention of CVD for at least 3 consecutive months and did not receive anti-coagulants or anti-platelets. Data were collected from electronic medical records from January 2014 to December 2018. CKD diagnosis was based on an estimated glomerular filtration rate of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Department of Nephrology and Hypertension, Meir Medical Center, Kfar Saba, Israel.
- Department of Nursing, School of Health Professions, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Avi, Israel.
- Department of Cardiology, Meir Medical Center, Kfar Saba, Israel.
- Division of Pulmonary Medicine, Barzilai University Medical Center, Ashkelon, Israel.
- Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.
Zitieren
APA
Schwartz Yoskovitz, G., Schwartz Yoskovitz, M., Haim-Pinhas, H., Saban, M., Pereg, D., Wand, O., Rozenberg, I., Benchetrit, S., & Cohen-Hagai, K. (2024). Risk Factors for Major Bleeding among Patients with Chronic Kidney Disease Treated with Acetylsalicylic Acid. Kidney and Blood Pressure Research. https://doi.org/10.1159/000542500
Vancouver
Schwartz Yoskovitz G, Schwartz Yoskovitz M, Haim-Pinhas H, Saban M, Pereg D, Wand O, et al. Risk Factors for Major Bleeding among Patients with Chronic Kidney Disease Treated with Acetylsalicylic Acid. Kidney and Blood Pressure Research. 2024. doi:10.1159/000542500
BibTeX
@article{SchwartzYoskovitz2024,
author = {Schwartz Yoskovitz, Gil and Schwartz Yoskovitz, Meytal and Haim-Pinhas, Hadar and Saban, Mor and Pereg, David and Wand, Ori and Rozenberg, Ilan and Benchetrit, Sydney and Cohen-Hagai, Keren},
title = {Risk Factors for Major Bleeding among Patients with Chronic Kidney Disease Treated with Acetylsalicylic Acid},
journal = {Kidney and Blood Pressure Research},
year = {2024},
doi = {10.1159/000542500}
}
EUVIMED